Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol.

@article{GallegosCastorena2009ImprovedTR,
  title={Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol.},
  author={Sergio Gallegos-Castorena and Aurora Medina-Sans{\'o}n and Oscar Gonzalez-Ramella and Fernando Antonio S{\'a}nchez-Zubieta and Armando Bernardo Mart{\'i}nez-Avalos},
  journal={Leukemia & lymphoma},
  year={2009},
  volume={50 7},
  pages={1132-7}
}
We analysed the results of three protocols from 1990 to 2005. Protocol I (1990-1996) consisted of a 2 year VAPA regime. Protocol II (1996-2003) on 1 year daunorubicin/cytarabine alternating with etoposide/cytarabine. Protocol III (2003-2005) on six cycles MRC AML 10 modified. Patients with de novo acute myeloid leukemia 0 to 18 years were included. Demographic and clinical characteristics were analysed. Patients with >100,000 leukocytes, M4 or M5 and primary CNS disease were considered high… CONTINUE READING